Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan: a review and new perspectives.

Giorgio Sandrini1, Armando Perrotta, Giuseppe Nappi

  • 1University of Pavia, University Centre for Adaptive Disorders and Headache, IRCCS C. Mondino Institute of Neurology Foundation, Pavia, Italy. gsandrin@unipv.it

Expert Review of Neurotherapeutics
|November 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hallmarks of primary headache: part 3 - cluster headache.

The journal of headache and pain·2025
Same author

Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.

Cephalalgia : an international journal of headache·2024
Same author

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Journal of neurology·2023
Same author

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Toxins·2023
Same author

Editorial: COVID-19: the neurorehabilitation perspective.

Frontiers in neurology·2023
Same author

Translation of surface electromyography to clinical and motor rehabilitation applications: The need for new clinical figures.

Translational neuroscience·2023
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Eletriptan, a 5-hydroxytryptamine(1B/1D) receptor agonist, is an effective and well-tolerated oral treatment for acute migraine attacks. It offers a favorable safety profile and cost-effectiveness compared to other migraine medications.

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Background:

  • Eletriptan is a second-generation 5-hydroxytryptamine(1B/1D) receptor agonist, classified as a triptan.
  • It is indicated for the acute treatment of migraine headaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of eletriptan for acute migraine treatment.
  • To assess the pharmacokinetic and pharmacodynamic profile of eletriptan.
  • To compare the cost-effectiveness of eletriptan with other triptans.

Main Methods:

  • Preapproval development program involving over 11,000 patients.
  • Treatment of more than 74,000 migraine attacks.
  • Clinical trials assessing efficacy, safety, tolerability, and cost-effectiveness.

Related Experiment Videos

Main Results:

  • Eletriptan demonstrated a favorable pharmacokinetic and pharmacodynamic profile, including bioavailability, half-life, and cranial artery selectivity.
  • Clinical trials confirmed eletriptan as a highly effective and well-tolerated oral therapy for acute migraine.
  • Eletriptan exhibited a superior cost-effectiveness profile compared to other agents in its class.

Conclusions:

  • Eletriptan is a highly effective and safe oral treatment option for acute migraine.
  • Its favorable pharmacokinetic and pharmacodynamic properties contribute to its efficacy.
  • Eletriptan presents a compelling cost-effective therapeutic choice for migraine management.